A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate

por Fakhouri, Walid, Wang, Xiaofei, de La Torre, Inmaculada, Nicolay, Claudia
Publicado 2020

Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis

por Fakhouri, Walid, Sapin, Christophe, Holzkaemper, Thorsten, de la Torre, Inmaculada
Publicado 2021

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis

por Lopez-Romero, Pedro, de la Torre, Inmaculada, Haladyj, Ewa, Aletaha, Daniel, Smolen, Josef S
Publicado 2022

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions

por Sacristán, José A., Díaz, Silvia, de la Torre, Inmaculada, Inciarte-Mundo, José, Balsa, Alejandro
Publicado 2019

Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotr...

por López-Romero, Pedro, Martinez-Gamboa, Lorena, Bang, Holger, de la Torre, Inmaculada, Holzkämper, Thorsten, Feist, Eugen
Publicado 2020

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

por Emery, Paul, Durez, Patrick, Hueber, Axel J., de la Torre, Inmaculada, Larsson, Esbjörn, Holzkämper, Thorsten, Tanaka, Yoshiya
Publicado 2021

Expression of 9G4 idiotope on autoantibodies to citrullinated peptides in patients with early inflammatory arthritis and established rheumatoid arthritis

por Moura, Rita A, de la Torre, Inmaculada, Leandro, Maria J, Edwards, Jonathan CW, Fonseca, João E, Cambridge, Geraldine
Publicado 2012

Neutralizing monoclonal antibodies for treatment of COVID-19

por Taylor, Peter C., Adams, Andrew C., Hufford, Matthew M., de la Torre, Inmaculada, Winthrop, Kevin, Gottlieb, Robert L.
Publicado 2021

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2

por Nathan, Ramesh, Shawa, Imad, De La Torre, Inmaculada, Pustizzi, Jennifer M., Haustrup, Natalie, Patel, Dipak R., Huhn, Gregory
Publicado 2021

Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target

por Taylor, Peter C., Van de Laar, Mart, Laster, Andrew, Fakhouri, Walid, Quebe, Amanda, de la Torre, Inmaculada, Jain, Saundra
Publicado 2021

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis

por Fautrel, Bruno, Alten, Rieke, Kirkham, Bruce, de la Torre, Inmaculada, Durand, Frederick, Barry, Jane, Holzkaemper, Thorsten, Fakhouri, Walid, Taylor, Peter C.
Publicado 2018

Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials

por Salvarani, Carlo, Sebastiani, Marco, Dieude, Philippe, Garcia, Miriam, Deberdt, Walter, Rogai, Veronica, de la Torre, Inmaculada, Inciarte-Mundo, José, Balsa, Alejandro
Publicado 2021

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

por Taylor, Peter C., Laedermann, Cedric, Alten, Rieke, Feist, Eugen, Choy, Ernest, Haladyj, Ewa, De La Torre, Inmaculada, Richette, Pascal, Finckh, Axel, Tanaka, Yoshiya
Publicado 2023

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

por Morand, Eric, Smolen, Josef S, Petri, Michelle, Tanaka, Yoshiya, Silk, Maria, Dickson, Christina, Meszaros, Gabriella, de la Torre, Inmaculada, Issa, Maher, Zhang, Hong, Dörner, Thomas
Publicado 2023

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib

por Combe, Bernard, Balsa, Alejandro, Sarzi-Puttini, Piercarlo, Tony, Hans-Peter, de la Torre, Inmaculada, Rogai, Veronica, Durand, Frederick, Witt, Sarah, Zhong, Jinglin, Dougados, Maxime
Publicado 2019

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

por Fautrel, Bruno, Kirkham, Bruce, Pope, Janet E., Takeuchi, Tsutomu, Gaich, Carol, Quebe, Amanda, Zhu, Baojin, de la Torre, Inmaculada, De Leonardis, Francesco, Taylor, Peter C.
Publicado 2019

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

por Taylor, Peter C., Bieber, Thomas, Alten, Rieke, Witte, Torsten, Galloway, James, Deberdt, Walter, Issa, Maher, Haladyj, Ewa, De La Torre, Inmaculada, Grond, Susanne, Wollenberg, Andreas
Publicado 2023

Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52

por Behrens, Frank, Leage, Soyi Liu, Sapin, Christophe, Baou, Celine El, De La Torre, Inmaculada, Meszaros, Gabriella, Schett, Georg, Combe, Bernard, van den Bosch, Filip, Gossec, Laure
Publicado 2021

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus

por Dörner, Thomas, Tanaka, Yoshiya, Dow, Ernst R, Koch, Alisa E, Silk, Maria, Ross Terres, Jorge A, Sims, Jonathan T, Sun, Zhe, de la Torre, Inmaculada, Petri, Michelle
Publicado 2022

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therap...

por Alten, Rieke, Burmester, Gerd R., Matucci-Cerinic, Marco, Salmon, Jean-Hugues, Lopez-Romero, Pedro, Fakhouri, Walid, de la Torre, Inmaculada, Zaremba-Pechmann, Liliana, Holzkämper, Thorsten, Fautrel, Bruno
Publicado 2022